Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
This randomized phase II trial studies how well obinutuzumab with or without umbralisib,
lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa
follicular lymphoma that has come back or does not respond to treatment. Immunotherapy with
obinutuzumab, may induce changes in body''s immune system and may interfere with the ability
of tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use
substances made from living organisms that may stimulate or suppress the immune system in
different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as
cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and
bendamustine, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving obinutuzumab with or without umbralisib, lenalidomide, or combination
chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.